There were 44 888 new cases of lung cancer in the United Kingdom In 2012, making it the second most common cancer, representing 13% of all new cancers ([@bib9]). In the same year, there were 35 371 deaths; 10-year survival is 5%. Options for improving outcomes in lung cancer are either by diagnosing at an earlier stage, potentially allowing curative surgery, or by improving treatments. Options for earlier stage diagnosis include: screening programmes with low-dose CT for people at high risk ([@bib24]); targeted public awareness campaigns to encourage people with symptoms to present earlier ([@bib2]; [@bib18]); GPs investigating higher risk patients with symptoms more quickly (as in this trial); allowing GPs access to low-dose CT ([@bib15]); and the development of predictive biomarkers. There is systematic review evidence that, for lung cancer, the evidence that timelier diagnosis is associated with better outcomes is equivocal ([@bib25]); however the higher quality studies reported in this review do show an association ([@bib8]; [@bib23]; [@bib38]), suggesting that there is merit in expediting the diagnosis of people presenting symptomatically.

The diagnosis of lung cancer in general practice can be complex and difficult ([@bib27]) and can therefore be 'easily missed\' ([@bib26]). The symptom signature of lung cancer is variable ([@bib35]), and many patients consult with their general practitioner several times before referral or investigation ([@bib21]; [@bib6]). In England and Wales, diagnostic activity for cancer is guided by the National Institute for Health and Care Excellence (NICE); their 2005 guidelines ([@bib29]) were updated in 2015 ([@bib30]). In this trial we hypothesised that an intervention to lower the NICE symptom threshold for investigation 'extra-NICE\' may improve clinical outcomes in lung cancer and the cost-effectiveness of lung cancer diagnosis. Our definition of 'extra-NICE\' (as compared with [@bib29] as these were in place at the time of the trial) was urgent referral for a chest X-ray for patients aged 60 years or over presenting in general practice with a new or altered cough of any duration, increased breathlessness, or wheezing (whether or not associated with purulent sputum), and who were either current smokers or ex-smokers with a 10 or more pack-years of smoking. At the time of the trial, the [@bib29] guidelines recommended chest X-ray after 3 weeks of symptoms in these patients. The new guidelines ([@bib30]) were published after the trial closed, recommend chest X-ray within 2 weeks in people aged 40 and over if they have two or more of selected unexplained symptoms (cough, fatigue, shortness of breath, chest pain, weight loss, appetite loss), or one of these if they have ever smoked.

This trial aimed to assess the feasibility and inform the design of a definitive, fully powered, UK-wide, Phase III clinical trial of a change to the NICE guidelines for urgent investigation of suspected lung cancer in patients aged over 60. In particular, this paper reports the results and lessons drawn from the development work and the mixed methods feasibility trial that set out to determine: the acceptability of trial design and materials; the training and recruitment of practices; the recruitment and randomisation of patients; appropriate methods for collection of wider clinical and health economics data in a full trial; and the views of participants and non-participants on recruitment and randomisation, and health-care professionals. The trial utilises a combination of workshop, health economics, quality of life, qualitative, and quantitative methods, examining the feasibility of a full trial.

Materials and methods
=====================

ELCID (Early Lung Cancer Investigation and Diagnosis) was a randomised, parallel group, unblinded, feasibility trial carried out in general practices in Wales and Yorkshire. A Working Group was formed before recruitment and randomisation with key stakeholders. It aimed to identify the best way to train GPs to identify and recruit eligible patients into the trial, and to identify the most effective method of presenting the trial (and randomisation) to patients. The outputs from this Working Group informed some of the practicalities of recruiting practices and participants and maximising data collection.

Study design, randomisation, sample size considerations, data collection procedures, and planned statistical methods have been published elsewhere ([@bib17]). Briefly, patients aged over 60 years, who were either smokers or ex-smokers with 10 or more pack-years of smoking history, and who presented at a general practice with a new or altered cough of any duration, or increased breathlessness or wheezing (whether or not associated with purulent sputum), were invited to participate. Patients who qualified for urgent referral for chest X-ray under [@bib29] guidelines, or who had had a chest X-ray or CT scan of the chest in the last 3 months, or who needed a chest X-ray within next 3 weeks, or who had previously been diagnosed with cancer and who had a life expectancy of less than 1 year, were ineligible.

Initially, all general practices in the four Health Boards in South east Wales were invited to participate in the trial. In addition, six practices in Yorkshire were recruited by the local research network (as were a further six practices from north Wales halfway through the trial -- see later). Patients were identified either at presentation or, in some practices where resources existed to do so, by looking through the records of the previous week\'s consultations. Patients identified at presentation were introduced to the trial and invited to consent or given a future appointment at which eligibility could be confirmed and consent could be taken. Patients identified through medical records were invited to make an appointment to discuss the trial, eligibility, and consent.

The trial aimed to assess: Key design parameters (prevalence of 'extra-NICE\' symptoms, trial consent rate, and lung cancer rate).Whether the intervention caused increased anxiety or depressionThe outcomes of the chest X-rays.The acceptability of trial procedures to participants and recruiters.The best ways of collecting trial data (patient recall, GP records, and routine data sets).

The study was developed on behalf of the NCRI Primary Care Clinical Studies Group, funded by the UK National Awareness and Early Diagnosis Initiative (NAEDI), sponsored by Bangor University, and coordinated by the Wales Cancer Trials Unit and South East Wales Trials Unit at Cardiff University. The study was approved by a UK multicentre ethics committee and carried out in accordance to the declaration of Helsinki and all UK regulatory requirements.

Those who were eligible and provided written informed consent were then individually randomised (1 : 1) to either an urgent chest X-ray or usual care ([@bib29]). Patients were randomised and informed of their allocation before being given a suite of questionnaires to complete ([Box 1](#box1){ref-type="boxed-text"}). The same questionnaires were posted to patients 2 months later. Twelve months after randomisation, general practices were contacted to provide follow-up information on the outcomes of any chest X-rays, health service resource use, and clinical outcomes. Data from the Welsh Cancer Intelligence and Surveillance Unit (WCISU) were used to verify the lung cancer data provided by general practices at 12 months (Wales only). The CTU staff maintained regular contact with the practices throughout the study. Full excess treatment and service support costs were provided. In order to incentivise practices further, there were occasional prizes for practices for best or most improved recruitment.

Randomisation
-------------

Randomisation took place centrally via the Bristol Randomised Trials Collaboration using either an automated telephone or a secure online service. Participants were randomised using minimisation with a random element (80 : 20) stratified by general practice, age (\<75, ⩾75), and chronic obstructive pulmonary disease diagnosis.

Statistical analysis
--------------------

The sample size was based on modelling work using the CAPER-lung database, which contains all primary-care consultations, symptoms, and investigations in the 2 years before diagnosis for a 5-year cohort of 247 lung cancer cases ([@bib16]; [@bib3]). We estimated that 0.77% of practice patients would be eligible for the trial in a year, that as many as 70% of those may be recruited, and of those recruited, 2.4% would develop lung cancer ([@bib17]). The trial aimed to recruit a sample size of 386 for reasonable precision around these estimates: the proportion of eligible patients in United Kingdom practices per year (0.77%, 95% confidence intervals (CIs): 0.70--0.83%) and of those recruited, the proportion developing lung cancer within 12 months (2.4%, 95% CIs: 0.9--3.9%).

Data were analysed using the STATA SE 14 statistical package (StataCorp LP, 4905 Lakeway Drive, TX, USA) according to intention-to-treat. All analyses were pre-specified *a priori*. When determining the lung cancer data (proportion diagnosed, stage of lung cancer, performance status, and radical treatment) the WCISU data set was taken as correct if it differed from the general practice data. Recruitment rates were assessed by: Primary Care Research Incentive Scheme (PiCRIS) level -- a Welsh Governmental funding and support scheme for general practices ([@bib28]); practice size; and months open to recruitment. We compared the completion rates of all questionnaires by trial arm, using *χ*^2^-tests. Subgroup analyses of completion of all questionnaires was also assessed by age (\<75 *vs* ⩾75 years), gender, post-randomisation anxiety, ethnicity, and smoking status. Post-randomisation anxiety and depression median scores were compared using Mann--Whitney tests. Subgroup analyses of anxiety and depression by age (\<75 and ⩾75 years), gender, and smoking status (current or ex-smoker) using Mann--Whitney tests were also performed. Differences in anxiety/depression scores between arms at 2 months post randomisation were assessed using multiple linear regression, with treatment arm and post-randomisation score as covariates in a base model. Subgroup analyses were performed by: repeating this model by age (\<75 or ⩾75), gender, and smoking history (current or ex).adding age, gender, or smoking history to the base model together with an interaction with treatment arm.

To ensure the validity of the linear regressions, checks were made for evidence of non-normality of residuals using Shapiro--Wilk tests and kernel density, normal probability and normal quantile plots, and heteroscedasticity using residuals *vs.* fits plots. No adjustment was made for multiple testing.

Health economics
----------------

Health economic data were collected post randomisation and at 2 months as shown in [Box 1](#box1){ref-type="boxed-text"}. The health service use information from the patients was compared with data about resource use collected from the GPs to ascertain the most appropriate method of capturing these data in the full trial. Data were analysed using the IBM SPSS Statistics Version 22 statistical package (IBM Corp., Armonk, NY, USA). The agreement analysis examined the level of agreement between the patient and GP as information sources. Data included: investigations ('Other\' chest X-ray (i.e., chest X-ray not including the one received on the ELCID trial as part of the intervention), CT scan, MRI scan, and PET-CT scan) performed on patients by 2 months. The Kappa (*κ*) statistic was employed to test investigation use agreement ([@bib37]). The Landis and Koch standard scales for strength of agreement for the *κ* coefficient were applied ([@bib20]).

Results
=======

Practice and patient recruitment
--------------------------------

The acceptability of the trial design was determined by the Working Group, and was reflected in the successful initial recruitment in Wales and Yorkshire. Twenty-eight practices were recruited from Wales and six from Yorkshire. However, three Welsh sites withdrew from the study without recruiting a participant. Twenty-two of the remaining 31 practices randomised 255 participants between 8 November 2012 and 9 April 2014. The CONSORT flow diagram is shown in [Figure 1](#fig1){ref-type="fig"}.

The acceptability of the trial design was determined by the Working Group, and was reflected in the successful initial recruitment in Wales and Yorkshire. A total of 28 practices were initially recruited (22 South east Wales and 6 in Yorkshire), of which three later withdrew, without recruiting any patients. Halfway through the trial, an additional six practices were recruited from north Wales by the local research network to boost recruitment. Twenty-two of the remaining 31 practices randomised 255 participants between 8 November 2012 and 9 April 2014. Nine sites failed to recruit a single participant. Those that failed to recruit cited lack of resources or lack of eligible patients as reasons. The CONSORT flow diagram is shown in [Figure 1](#fig1){ref-type="fig"}.

Recruitment screening log data were poorly completed generally, but two practices provided reliable data, based on agreement between participation recorded on screening logs and central randomisation data. From these two practices, the prevalence of the trial eligibility criteria was calculated as 0.75% of practice registrations per year (214 eligible people per year from a combined registered population of 28 502; 95% CI 0.65--0.86%). In addition, from these two sites, the proportion of eligible patients who agreed to participate was 74 out of 223 (33.2% 95% CI 27.0--39.8%).

The recruitment of participants by practice size, known research activity (PiCRIS scheme -- Welsh practices only), and number of months open to recruitment is shown in [Table 1](#tbl1){ref-type="table"}. This shows that: practice size had little overall effect on the number of randomised patients per 1000 per year; the PiCRIS level of the practice had little effect on the number of randomised patients per 1000 per year, other than 'sessional\' (the highest level of participation) practices having a higher randomisation rate; and that practices which were open to recruitment for shorter periods of time had a higher rate of recruitment.

Baseline comparability between the groups
-----------------------------------------

The breakdown of the variables, overall, and by trial arm, are shown in [Table 2](#tbl2){ref-type="table"}. This shows that the demographics (gender, age, ethnicity, duration and highest level of education, and economic situation), presenting symptoms, pre-existing co-morbidity, and numbers of recent chest X-rays had similar distributions in each trial arm.

Fidelity of the intervention
----------------------------

About 113 out of 127 (89.0%) patients in the intervention arm received a total of 148 chest X-rays within 12 months. Of these, 88 patients (69.3%) had their first X-ray within 7 days, 100 (78.7%) within 14 days, and 104 (81.9%) within 21 days. Forty-three out of 128 (33.6%) participants in the control arm also received a total of 50 chest X-rays within 12 months. Of these, 3 patients (2.3%) had their first X-ray within 7 days, 10 (7.8%) within 14 days, and 13 (10.2%) within 21 days. The median times to chest X-ray in the intervention and control groups were 3 days (interquartile range (IQR) 1--7), and 71 days (IQR 17--233, respectively). In the intervention arm, 10 (7.9%) patients had repeat chest X-rays within 3 months (8 had 1 repeat, 2 had 2 repeats with \<3 months between each). In the control arm, 3 (2.8%) patients had repeat chest X-rays (1 patient had 1 repeat, 2 had 2 repeats with \<3 months between each).

Significant adverse events
--------------------------

Three patients in the control arm died, one due to lung cancer (52 days post randomisation), one due to myocardial infarction (178 days post randomisation), and one due to cardiac arrest (216 days post randomisation). One patient in the intervention arm died, due to lung cancer; time to death was 95 days. None of these events were thought to be related to study procedures.

Survey responses and Hospital Anxiety and Depression Scores
-----------------------------------------------------------

Survey responses are shown in [Table 3](#tbl3){ref-type="table"}. This shows that completion of all tools post randomisation was good (89.4%), and equal in both the groups. Completion of tools at 2 months was also similar between the two groups, with just less than two-thirds completion. There was no evidence for differences in completion between arms within subgroups based on age, sex, post-randomisation anxiety, or smoking history (data not presented). Hospital Anxiety and Depression Scores are also presented in [Table 3](#tbl3){ref-type="table"}. There was no evidence of a difference in post-randomisation anxiety scores between trial arms (median (IQR): 6 (3--8) in control *vs* 5 (3--9) in intervention, *z*=0.32; *P*=0.75) or between arms by subgroups based on age, sex, or smoking history (*P*⩾0.35). Similarly, there was no evidence for a difference in post-randomisation depression between arms (median (IQR): 6 (3--8) in control *vs* 5 (3--9) in intervention, *z*=−0.12; *P*=0.91) or between arms by subgroups based on age, sex, or smoking history (*P*⩾0.56). The 2-month results presented in [Table 3](#tbl3){ref-type="table"} suggest no difference in either anxiety or depression between trials arms except when performing subgroup analyses using age. For both anxiety and depression, the model that included age as a covariate had significant age-trial arm interaction terms (*P*=0.02 and 0.05, respectively). There was a significantly higher anxiety (median (IQR): 7.5 (4.5--9) *vs* 4 (3--7), *t*=−2.97; *P*=0.006) and depression (7.5 (4.5--9) *vs* 4 (3--7), *t*=−2.67; *P*=0.013) score in the control arm in the ⩾75 age group although the number of participants in this subgroup was small (*n*=33).

Chest X-ray outcomes, cancer diagnoses, other diagnostic investigations, and other diagnoses
--------------------------------------------------------------------------------------------

[Table 4](#tbl4){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"} show the outcomes of the chest X-rays. There were more normal results in the intervention arm (105 (70.9%) *vs* 25 (50%)) but more patients were found to have at least one abnormality in the intervention arm (31 (25.8%) *vs* 20 (16.3%)). In the intervention arm, four chest X-rays from three participants were suspicious of lung cancer (3 of which led to CT scans within 3 weeks of X-ray, 2 of which led to a diagnosis of lung cancer) compared with one in the control arm (which led to a diagnosis of lung cancer within 34 days of randomisation without CT scan); 20 days of chest X-ray. Data from WCISU confirmed the three lung cancer diagnoses reported from primary care. In the intervention arm, one was stage IA, adenocarcinoma, WHO performance status 0, diagnosis 58 days post randomisation, and the participant received radical treatment. The other was stage III, missing tumour type, performance status 3, diagnosis 80 days post randomisation, and the participant received no radical treatment. In the control arm, this was a small cell tumour, stage 4 at diagnosis, performance status 2, diagnosis 39 days post randomisation and the participant received no radical treatment. Thus, 3 out of 256, that is, 1.2% (95% CIs: 0.2--3.4%) of trial participants were diagnosed with lung cancer. A flow chart showing pathways to other outcomes from normal and abnormal chest X-rays, including further investigations for both trial arms is shown in [Figure 2](#fig2){ref-type="fig"}.

Exploration of the most appropriate measure of collecting health resource use data -- agreement analysis results
----------------------------------------------------------------------------------------------------------------

[Table 5](#tbl5){ref-type="table"} shows the results of agreement between the resource use data self-reported by the patients and the resource use data collected routinely from the GP records. Overall there was a high degree of agreement between patients\' self-reported data and routine-based health-care resource use data, with values ranging from 67.67 to 97.60%. Agreement was the highest for PET-CT scan and lowest for 'other\' chest X-ray. However, the strength of agreement was considerably below average, ranging from fair agreement (*κ*=0.32, s.e. 0.18, 95% CI −0.03--0.66) for CT scan, to slight agreement (*κ*=0.20, s.e. 0.06, 95% CI 0.08--0.31) for 'other\' chest X-ray. No results of kappa are presented for either MRI or PET-CT; this is because no comparison was possible as none were reported. The full findings from the health economics analysis will be reported elsewhere.

Discussion
==========

Summary of main findings
------------------------

This feasibility trial has achieved its targets in terms of assessing: key design parameters, impact on anxiety/depression, chest X-ray outcomes, the acceptability of trial procedures, and the best ways of collecting trial data. It supports the feasibility of conducting a Phase III trial. Our trial suggests that the prevalence of the trial eligibility criteria was 0.75% (95% CIs: 0.65--0.86%) of practice registrations per year, matching our estimate in the protocol. However, the proportion of eligible patients who agreed to participate was considerably lower than expected (33.2% 95% CI 27.0--39.8%), explaining our lower than anticipated recruitment of 255 participants rather than the target 386. In addition, the trial suggests that the proportion of trial participants who developed lung cancer was 1.2% (95% CIs: 0.2--3.4%) -- this is in keeping with our *a priori* estimate of 2.4%. The same three cancers identified within the practices were also identified by WCISU. The abnormal chest X-rays undertaken in both arms triggered further investigations, again as anticipated. We also identified more cardiac and other lung pathologies in the intervention than control group, although we are unsure of the clinical significance of this. We were able to collect questionnaires from patients\' post randomisation and at 2 months with acceptable return rates. There was some evidence that anxiety and depression may have been higher in the control arm in those aged ⩾75 years.

This was a challenging feasibility trial to undertake because we did not know at the outset whether it would be acceptable to recruit practices and patients to a study that individually randomised patients with possible lung cancer to quicker diagnostic testing. We were explicit in our patient recruitment materials that participants were at higher risk of lung cancer and that the intervention was a test to detect lung cancer earlier. We believe that this is the first trial that has recruited and randomised patients in this context. Through the use of good methods and engagement, such as a Working Group, training all relevant practice staff, practice payments for extra time taken, research network staff support wherever possible, use of practice databases to identify eligible patients wherever possible, we were able to recruit practices and participants albeit at a lower rate than anticipated.

Discussion of the findings within the context of the literature
---------------------------------------------------------------

### The acceptability of trial design and materials, the training and recruitment of practices, and the recruitment and randomisation of patients

The work that we put into the Working Group enabled us to make minor changes to the trial design that made the trial more acceptable to both practices and patients. This was demonstrated in our success in recruitment and randomisation. Although we thought that obtaining consent from patients may be more difficult, we elected to use an individually randomised design rather than a cluster design. This may have led to GPs having to take more time to explain the trial to patients accompanied by the administrative burden of individually randomising patients, with a consequent diminished consent rate. However, we found little evidence of contamination in the control arm seeking urgent chest X-rays.

### Anxiety and depression

Our finding of higher anxiety in the over 75 s in the control group fits with a Danish trial that participation in a randomised lung screening trial was associated with negative psychosocial consequences ([@bib1]).

### The views of patients and recruiters

The importance of qualitative work in feasibility studies in establishing best recruitment methods has been highlighted by others ([@bib13]; [@bib40]). We successfully engaged with patient trial participants, patient non-participants, and recruiters from practices. The findings from this, which will be reported in full elsewhere, will inform the design of the subsequent main trial. Briefly, recommendations are to ensure recruiting sites are equipped to reduce misconceptions and misunderstandings of trial purpose, processes, and interventions when seeking consent. There will be less emphasis on smoking in the patient-facing materials. In terms of recruitment sites, the need for a strong point of contact for trial promotion and knowledge of processes is advised.

### The appropriateness of methods for collection of wider clinical and health economics data in a full trial

The 2-month questionnaire return rates were \>60% -- thought to be crucial in surveys to avoid bias from outliers ([@bib19]). In the agreement analysis, the percentage of agreement between self-report data and routine-based health-care resource use data from patients\' GP records for all four types of investigations were generally high, and line with other studies ([@bib39]; [@bib5]). These findings suggest that self-report of health service use over a reasonably short recall period in this older population group seems valid. The completion rates for the tools that we used were acceptable, and we were able to collect useful information on presenting symptoms and co-morbidity. Quite importantly, we did not see a difference in anxiety and depression scores between trial arms. The fidelity of the intervention was good, in that 82% of participants in the intervention arm received a chest X-ray within 3 weeks. The proportion of participants in the control arm who received a chest X-ray was similar to what we anticipated.

Strengths and weaknesses
------------------------

The main strength of the study is that we have conducted a pragmatic feasibility individually randomised trial in primary care, and fully tested all of the processes involved for a full trial. The main weakness is that in the protocol we aimed to recruit 386 participants, but we only recruited 255. This has lowered the precision with which we can estimate the key parameters required in designing the Phase III trial. We are also aware that the age and smoking thresholds used in this trial are different from some of the screening trials. Our screening log data may not be generalisable as it was based on two practices only. In addition the number of patients recruited per practice varied, with two practices contributing a third of the participants.

Implications for policy, practice, and research
-----------------------------------------------

In summary, we believe that we have demonstrated the feasibility of this trial design. However, while this raises several significant challenges ([Box 2](#box2){ref-type="boxed-text"}), we believe that there is a need for a trial that aims to diagnose symptomatic lung cancer earlier. This hypothesis has been helped by a recent study that has estimated the symptom lead time in lung cancer (the duration of reported symptoms before diagnosis) finding no relationship between duration of symptoms and stage ([@bib7]). The data for this study were collected in the era before the considerable expansion of diagnostic services for suspected cancer had occurred, and it is possible that results in a study conducted now would differ. That paper also reported the concept of two populations with lung cancer who are identified in any programme of enhanced diagnostics: those whose symptoms are caused by the cancer, and those whose symptoms met criteria for investigation, but were not actually caused by the cancer.

In conclusion, we have demonstrated the feasibility of recruiting to an individually randomised controlled trial in primary care for earlier chest X-ray for patients at higher risk of lung cancer who present to primary care with new symptoms. We are now developing a Phase III trial with the intention of evaluating the effect of timelier symptomatic diagnosis on lung cancer outcomes. While NICE guidelines have changed since we undertook the feasibility trial, we believe that our findings will inform a trial of very similar design; that is, individual randomisation of people at greater risk for expedited investigation or usual care. Our findings are also likely to have implications for other studies of urgent investigation for serious conditions.

Ethics and trial registration
-----------------------------
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![**Consort diagram.** \*Box shows actual numbers from complete screening data from two sites. Figure in square brackets is the overall prediction using the numbers from the two sites as an estimate to predict likely screening at other sites that recruited at least one patient.](bjc2016414f1){#fig1}

![**Flow chart showing all outcomes from chest X-rays in both the groups.** I=Intervention, C=control.](bjc2016414f2){#fig2}

###### Breakdown of recruitment by practice size, known research activity (PiCRIS scheme), number of months open to recruitment

                                                                               **Participants randomised**  
  --------------------------------- ---------------- ---- ------------------- ----------------------------- ------
  **Practice size (patients)**                                                                              
  1st quartile                         up to 5252     8     3906.4 (1392.9)                35                0.92
  2nd quartile                         5253--8301     7     7221.9 (783.6)                 66                1.04
  3rd quartile                        8302--12 037    8     9911.4 (1037.2)                36                0.38
  4th quartile                       12 038--21 433   8    15 128.6 (3140.0)               118               1.18
  **Research activity**                                                                                     
  PiCRIS level 1                                      4      8724 (3656.1)                 19                0.45
  PiCRIS level 2                                      4    10 786.5 (4640.6)               19                0.46
  Sessional                                           6    12 877.5 (5409.0)               154               2.15
  None[a](#t1-fn2){ref-type="fn"}                     17    7459.8 (3840.8)                63                0.41
  **Months open**                                                                                           
  1st quartile                         up to 9.3      9      9693 (5789.5)                 94                1.48
  2nd quartile                        \>9.3--14.2     9     8166.6 (3090.5)                66                0.77
  3rd quartile                        \>14.2--16.2    6     9645.7 (5887.9)                55                0.71
  4th quartile                        \>16.2--18.2    7     9073.4 (4074.8)                40                0.42

Abbreviation: PiCRIS=Primary Care Research Incentive Scheme.

Includes English centres where PiCRIS funding is not available.

###### Baseline demographics, co-morbidity, symptoms, and previous chest X-rays of trial participants

                                                  **Control**          **Intervention**           **Overall**                    
  ----------------------------------------- ----------------------- ----------------------- ----------------------- ------ ----- -------
  Randomised -- *n*                                   128                    50.2                     127            49.8   255   100.0
  Gender                                                                                                                             
   Male                                               64                     50.0                     66             52.0   130   51.0
   Female                                             64                     50.0                     61             48.0   125   49.0
  Age                                                                                                                                
   Median (IQR)                              **67.3 (64.5--72.8)**   **67.9 (64.3--73.2)**   **67.5 (64.3--73.2)**               
   ⩾75 years old                                      23                     18.0                     26             20.5   49    19.2
   \<75                                               105                                             101                   206      
  Identification of eligibility                                                                                                      
   Routine consultation                               102                    79.7                     101            79.5   203   79.6
   COPD clinic                                         1                      0.8                      3             2.4     4     1.6
   Review of patient notes                            25                     19.5                     23             18.1   48    18.8
  Ethnicity                                                                                                                          
   White                                              127                    99.2                     126            99.2   253   99.2
   Other                                               0                      0.0                      1             0.8     1     0.4
   Missing                                             1                      0.8                      0             0.0     1     0.4
  Years of f/t education from age 5                                                                                                  
   Median (IQR)                                **10 (10--11.5)**        **10 (10--11)**         **10 (10--11)**                  
   Missing                                             0                       1                       1                             
  Highest education level                                                                                                            
   University                                         12                      9.4                      6             4.7    18     7.1
   Professional training                              25                     19.5                     24             18.9   49    19.2
   Secondary school                                   86                     67.2                     93             73.2   179   70.2
   Did not attend secondary school                     5                      3.9                      3             2.4     8     3.1
   Missing                                             0                      0.0                      1             0.8     1     0.4
  Economics                                                                                                                          
   Find it a strain to get by                         10                      7.8                     11             8.7    21     8.2
   Have to be careful about money                     44                     34.4                     45             35.4   89    34.9
   Able to manage without much difficulty             40                     31.3                     41             32.3   81    31.8
   Quite comfortably off                              30                     23.4                     24             18.9   54    21.2
   Prefer not to answer                                4                      3.1                      6             4.7    10     3.9
  Co-morbidity                                                                                                                       
   At least one co-morbidity                          61                     47.7                     76             59.8   137   53.7
   Chronic pulmonary disease                          37                     60.7                     41             53.9   78    56.9
   Median Charlson score (IQR)                   **3 (2--4)**            **3 (2--4)**            **3 (2--4)**                    
  Previous CXRs in last 12 months                                                                                                    
   Had one                                            22                     17.2                     21             16.5   43    16.9
   Not had one                                        106                    82.8                     106            83.5   212   83.1
  Smoking history                                                                                                                    
   Current smoker                                     62                     48.4                     59             46.5   121   47.5
   Ex-smoker                                          66                     51.6                     68             53.5   134   52.5
   Pack-years -- median (IQR)                   **30 (20--45)**         **31 (20--45)**         **3 (20--45)**                   
  Presenting symptoms                                                                                                                
   Cough only                                         35                     27.3                     38             29.9   73    28.6
   Cough+other symptoms                               60                     46.9                     60             47.2   120   47.1
   Breathlessness ± others                             7                      5.5                      3             2.4    10     3.9
   Missing                                            26                     20.3                     26             20.5   52    20.4

Abbreviations: COPD=chronic obstructive pulmonary disease; CXR=Chest X-ray; IQR=interquartile range.

No missing data except where stated.

###### Survey response at baseline and 2 months, and Hospital Anxiety and Depression Scores -- 2-month questionnaires

                                                **Control**   **Intervention**   **Overall**                                                                                                                                                             
  -------------------------------------------- ------------- ------------------ ------------- ------------------ ----- ------ --------------------------------------------------------------------------- ---------------------------------------------- --------------------------------------------------------------
  Baseline data returned -- *n* (%)                 128             50.2             127             49.8         255   100                                                                                                                                                             
  **Baseline questionnaires**                                                                                                                                                                                                                            
  All questionnaires                                118             92.2             110             86.6         228   89.4                                     2.09                                                          0.15                                                     
   ICECAP                                           123             96.1             121             95.3         244   95.7                                     0.10                                                          0.75                                                     
   EQ-5D                                            124             96.9             123             96.9         247   96.9                                    \<0.001                                                        0.99                                                     
   CSRI                                             121             94.5             111             87.4         232    91                                      3.95                                                          0.05                                                     
   HADS                                             125             97.7             122             96.1         247   96.9                                     0.53                                                          0.47                                                     
  **2-month questionnaires**                                                                                                                                                                                                                             
  All 2-month questionnaires                        82              64.1             84              66.1         166   65.1                                     0.12                                                          0.73                                                     
   ICECAP                                           84              65.6             93              73.2         177   69.4                                     3.02                                                          0.22                                                     
   EQ-5D                                            85              66.4             92              72.4         177   69.4                                     2.32                                                          0.31                                                     
   CSRI                                             82              64.1             85              66.9         167   65.5                                     1.33                                                          0.51                                                     
   HADS                                             85              66.4             92              72.4         177   69.4                                     2.32                                                          0.31                                                     
  **HADS score from 2-month questionnaires**                                                                                                                                                                                                             
                                                  ***n***     **Median (IQR)**     ***n***     **median (IQR)**                **Linear regression test statistic (*****t***)[a](#t3-fn2){ref-type="fn"}   ***P*****-value**[a](#t3-fn2){ref-type="fn"}   ***P*****-value for interaction**[b](#t3-fn3){ref-type="fn"}
  Anxiety                                                                                                                                                                                                                                                                               
   All patients                                     85            7 (4--9)           92           6 (3--9.5)                                                     −0.7                                                          0.49                                                     
   Age \<75                                         73            7 (4--8)           71           6 (3--10)                                                       0.3                                                          0.76                                                   0.02
   Age⩾75                                           12          7.5 (4.5--9)         21            4 (3--7)                                                      −2.97                                                        0.006                                                     
   Male                                             39            6 (3--8)           51            6 (3--8)                                                      0.09                                                          0.93                                                   0.52
   Female                                           46            7 (5--9)           41           5 (3--11)                                                      −1.01                                                         0.32                                                     
   Current smoker                                   40            7 (5--8)           40           6 (4--12)                                                      0.39                                                          0.7                                                    0.23
   Ex-smoker                                        45            6 (3--9)           52            5 (3--7)                                                      −1.18                                                         0.24                                                     
  Depression                                                                                                                                                                                                                                                                            
   All patients                                     85            7 (4--9)           92           6 (3--9.5)                                                     −0.59                                                         0.56                                                     
   Age \<75                                         73            7 (4--8)           71           6 (3--10)                                                      0.26                                                          0.8                                                    0.05
   Age⩾75                                           12          7.5 (4.5--9)         21            4 (3--7)                                                      −2.67                                                        0.013                                                     
   Male                                             39            6 (3--8)           51            6 (3--8)                                                      0.21                                                          0.83                                                   0.46
   Female                                           46            7 (5--9)           41           5 (3--11)                                                      −0.99                                                         0.33                                                     
   Current smoker                                   40            7 (5--8)           40           6 (4--12)                                                      0.41                                                          0.69                                                   0.31
   Ex-smoker                                        45            6 (3--9)           52            5 (3--7)                                                      −1.07                                                         0.29                                                     

Abbreviations: CSRI=Client Service Receipt Inventory; EQ-5D=EuroQol 5 Dimensional Health State Questionnaire; HADS=Hospital Anxiety and Depression Scores; ICECAP=ICEpop CAPability measure for Older people; IQR=interquartile range

Base model in subgroup.

Base model plus subgroup variable plus subgroup treatment arm interaction in all patients.

###### Chest X-ray outcomes

                                                                                                                      **NICE**    **Extra-NICE**         
  ------------------------------------------------------------------------------------------------------------------ ---------- ------------------ ----- ---------------
  12-month follow-up expected                                                                                           125                         125          
  CRF return                                                                                                            123                         120          
  Number of patients receiving at least one chest X-ray in 12 months (*n*)                                               43            35.0         113       94.2
  Time to first chest X-ray -- median (range (IQR)) days (if within 12 months)                                           71      2--348 (17--233)    3    0--308 (1--7)
  Number of chest X-rays within 12 months (*n*)                                                                          50                         148          
  Normal                                                                                                                 25            50.0         105       70.9
  Suspicious of lung cancer                                                                                              1             2.0           4         2.7
  Missing data                                                                                                           0             0.0           1         0.7
  Other abnormality                                                                                                      24             48          38        25.7
  Number of participants[a](#t4-fn2){ref-type="fn"} with at least one abnormality (lung cancer suspected or other)       20            16.3         31        25.8
  Other abnormalities diagnosis                                                                                          24                         38           
  Non-lung abnormalities                                                                                                                                         
   Cardiac/aortic abnormalities, for example, cardiomegaly, widened aortic root                                          6             25.0         14        36.8
  Lung abnormalities                                                                                                                                             
   Suspected infection                                                                                                   5             20.8          5        13.2
   Benign lung disease                                                                                                   10            41.7         12        31.6
   COPD                                                                                                                  2             8.3           2         5.3
   Emphysema                                                                                                             1             4.2           1         2.6
   Pleural plaques                                                                                                       0             0.0           2         5.3
   No change from previous                                                                                               0             0.0           2         5.3

Abbreviations: COPD=chronic obstructive pulmonary disease; CRF=case report form data; IQR=interquartile range; NICE=National Institute for Health and Care Excellence.

Some patients had more than one X-ray.

###### Level of agreement between self-reported data and case report form data collected from the GP records (routinely collected data) by type of investigations use in the 2 months post baseline (*n*=167)

  **Type of investigations**      **CRF (+), SR (+)**   **CRF (+), SR (−)**   **CRF (−), SR (+)**   **CRF (−), SR (−)**   **Agreement (%)**
  ------------------------------- --------------------- --------------------- --------------------- --------------------- -------------------
  'Other\' chest X-ray, *n* (%)   12 (7.19)             2 (1.20)              52 (31.14)            101 (60.48)           113 (67.66)
  CT scan, *n* (%)                2 (1.20)              1 (0.60)              7 (4.19)              157 (94.01)           159 (95.21)
  MRI scan, *n* (%)               0 (0.00)              0 (0.00)              9 (5.39)              158 (94.61)           158 (94.61)
  PET-CT scan, *n* (%)            0 (0.00)              0 (0.00)              4 (2.40)              163 (97.60)           163 (97.60)

Abbreviations: CT=computed tomography; CRF=case report form data; ELCID=Early Lung Cancer Investigation and Diagnosis; GP=general practice; MRI=magnetic resonance imaging; PET-CT=positron emission tomography--computed tomography; SR=self-reported data.

Other\' chest X-ray means additional CXR received following the CXR received on the ELCID trial as part of the ELCID intervention. The differences reported in this table may reflect a change in wording from the original CRF, that was subsequently improved from 'Chest X-Ray\' to 'Chest X-Ray (not including any received on the ELCID trial)\'.

CRF (−) means that the routine data did not indicate an investigation; CRF (+) means that the routine data indicated an investigation; SR (−) means that the respondent did not indicate an investigation; SR (+) means that the respondent indicated an investigation.

###### Post randomisation and 2 months questionnaires

Hospital Anxiety and Depression Scale (HADS) ([@bib41]).

Client Service Receipt Inventory (CSRI) ([@bib4]; [@bib34]; [@bib33]).

ICEpop CAPability measure for Older people (ICECAP-O) ([@bib10]).

EuroQol 5 Dimensional Health State Questionnaire (EQ-5D-3L) ([@bib12]; [@bib11]).

###### Challenges for a Phase III trial

What should be used as a primary outcome measure? Survival, stage shift, or some other proxy measure?What should be the nature of 'usual care\' in the control group, now that NICE guidance has changed?Should we be using low-dose CT rather than chest X-ray for imaging? Or indeed chest X-ray followed by CT for normal and abnormal chest X-rays? There is an emerging literature regarding allowing GPs access to low-dose CT, for patients with symptoms where lung cancer is suspected ([@bib15]). However, a recent cluster trial in Denmark reported little improvement in stage or times to diagnosis with direct access to CT ([@bib14]). This trial had different inclusion criteria to our design, hence it is unknown what effect on outcomes an individually randomised trial of direct access to CT for 'extra-NICE\' symptoms would be. Whatever the nature of the intervention we have demonstrated the feasibility of the principle of a trial of urgent imaging in this population.Does the possibility of a screening programme complicate symptomatic diagnosis? While the landmark American NLST reported a 20% reduction in mortality ([@bib24]), only 27% of American lung cancer patients meet their inclusion criteria ([@bib32]). It is also unknown how attractive screening would be outside the highly motivated individuals participating in clinical trials and whether the results obtained in standard practice would be equivalent to those in the large, multidisciplinary academic centres participating in the clinical trials. Other drawbacks are the high prevalence of false-positive results and the risk of major complications in those diagnosed with benign nodules. In addition, people at high risk of lung cancer (smokers) have a relative disregard for their own health and express relative reluctance to consider CT screening, with only half saying that they would opt for surgery for a cancer diagnosed as a result of screening ([@bib36]). Recruitment into a lung cancer screening programme does not appear to affect likelihood of smoking cessation. Aside from these practical considerations, additional downsides of screening include overdiagnosis ([@bib31]), high cost and uncertain benefit, especially in Europe ([@bib22]), and that optimal follow-up algorithms have not yet been established. While screening may be an option in the future, it will not obviate the need for clinical diagnosis in patients presenting with symptoms.
